The difference in relative rate reductions highlights that tezepelumab acts mainly via the inhibition of epithelial-derived alarmin TSLP and subsequent shutdown of downstream type 2 inflammation, an observation supported by signals observed in the translational Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)71 and Effects of Anti-TSLP in Patients With Asthma (UPSTREAM)72 study (Fig 2). The gene discussed is TSLP; the disease is asthma.